An Open-Label, Long-Term Safety Study to Evaluate the Safety of the ZR-02-01 Matrix Transdermal Fentanyl Patch for the Treatment of Moderate to Severe Cancer Pain
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 24
- 试验地点
- 2
- 主要终点
- Number of participants with adverse events
研究概览
简要总结
The purpose of this study is to evaluate the safety of the matrix fentanyl patch ZR-02-01 in providing relief of cancer pain.
详细描述
This study will evaluate the safety of the matrix fentanyl patch. The study will be conducted in opioid-tolerant patients with moderate to severe cancer pain currently taking an around-the-clock opioid. Patients will discontinue their current opioid regimen and begin using ZR-02-01 as soon as possible under the direction of the physician investigator upon entry into the study. Patient's dose of ZR-02-01 will be determined by the investigator using sponsor-provided conversion. Pain therapy will be under the supervision of the physician investigator.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is at least 18 and no older than 75 years of age at the time of screening
- •Patient has a diagnosis of cancer
- •Patient has moderate to severe pain that is related to cancer or its treatment and is expected to last indefinitely and is currently taking an around-the-clock opioid to treat his/her pain
- •Patient is already receiving opioid therapy, has demonstrated opioid tolerance
- •A responsible adult caregiver is available in the event of an emergency at home
排除标准
- •Patient has uncontrolled or rapidly escalating pain as determined by the investigator
- •Patient has a history of substance abuse or has a substance abuse disorder
研究组 & 干预措施
ZR-02-01
ZR-02-01 matrix transdermal fentanyl patch
干预措施: Fentanyl Transdermal Matrix Patch ZR-02-01 (Drug)
结局指标
主要结局
Number of participants with adverse events
时间窗: 12 weeks
To evaluate the safety of long-term administration of the ZR-02-01 patch for the treatment of moderate to severe cancer pain
次要结局
- Pain intensity(12 weeks)
- Global Satisfaction satisfied)(12 weeks)